CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Myovant Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Myovant Sciences Ltd
50 Broadway
7th Floor
Phone: +44 2074003351p:+44 2074003351 London, SW1H 0DB  United Kingdom
This company was Merged or Acquired on 3/10/2023.
This company ceased filing statements with the SEC on 3/20/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20223/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Myrtle S.Potter 63 9/20/2018 9/20/2018
Principal Executive Officer and Director LynnSeely
Principal Financial and Accounting Officer FrankKarbe
15 additional Officers and Directors records available in full report.

Business Names
Business Name
MYOV
Myovant Holdings Ltd.
Myovant Sciences GmbH
4 additional Business Names available in full report.

General Information
Number of Employees: 579 (As of 3/31/2022)
Outstanding Shares: 97,235,316 (As of 1/20/2023)
Stock Exchange: NYSE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 8, 2024